Palatin Technologies, Inc. (AMEX: PTN), a biopharmaceutical company, has dedicated their efforts to developing peptide, peptide mimetic and small molecule agonist compounds. Their primary focus is on melanocortin and natriuretic peptide receptor systems, including acute hospital care products in the cardiovascular field, for treating congestive heart failure, hard-to-control hypertension as well as cardiac surgery organ protection. For further information, visit the Company’s web site at www.palatin.com.
- 17 years ago
QualityStocks
Palatin Technologies, Inc. (AMEX: PTN)
Tags Rodman & Renshaw
Related Post
-
Soligenix Inc. (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation
Designations granted by leading global regulatory agencies play a critical role in advancing drug-development programs.…
-
Safe Pro Group Inc. (NASDAQ: SPAI) Delivers Critical Security and Defense Solutions to Governments and Organizations
Safe Pro Group delivers AI, drone-based services, and ballistic protective gear, to customers in the…
-
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape
Recent research shows how chemotherapy and immunotherapy can complement each other when used together. Within…